3 results about "Conventional treatment" patented technology

The present invention relates to: an AAV-based PDE6B viral vector for treating retinitis pigmentosa, the AAV-based PDE6B viral vector containing a tissue-specifically expressed PDE6A promoter; and a use of thereof, and provides a gene therapy for treating retinitis pigmentosa caused by PDE6B gene deficiency. The in vivo therapeutic efficacy of seven types of AAV5-PDE6B vectors was confirmed using an AAV by using a PDE6A promoter that is tissue-specifically expressed in photoreceptor rod cells that develop retinitis pigmentosa. An AAV5-PDE6A-450-PDE6B vector was selected as a candidate due to exhibiting strong tissue-specific expression in photoreceptor rod cells under even off-target conditions, unlike the gene expression characteristics of an AAV5-CMV-PDE6B vector, and was tested so as to be usable in the development of a gene therapeutic agent for treating PDE6B-deficient retinitis pigmentosa patients. Therefore, the present invention, related to AAV5-PDE6B for retinitis pigmentosa treatment and containing a tissue-specifically expressed PDE6A promoter, provides retinitis pigmentosa patients with an important treatment option having improved safety, and can be expected to have fundamental therapeutic effects compared to conventional treatments.

This invention provides the application of a traditional Chinese medicine composition in the preparation of cardiovascular protective drugs after percutaneous coronary intervention (PCI) for myocardial infarction, specifically acute ST-segment elevation myocardial infarction (STEMI), with a TCM syndrome of "heart yang deficiency." The composition comprises raw Cornus officinalis, dried ginger, ginseng, Astragalus membranaceus, Atractylodes macrocephala, Alisma plantago-aquatica, Poria cocos, and Aconitum carmichaelii. The cardiovascular protective effects of this composition include improving cardiac function, inhibiting postoperative oxidative stress, reducing NT-proBNP, and decreasing the risk of cardiovascular events within one year post-surgery. It can be prepared as a decoction, oral liquid, or other dosage forms, and can be used in combination with conventional Western medicine treatments for synergistic effects. The composition of this invention is scientifically formulated, targets multiple points of action, and effectively addresses the problem of limited cardiovascular protection methods after PCI in STEMI patients, significantly improving patient prognosis and demonstrating good clinical application value.

The invention describes peptides with anticancer activity and exhibiting antagonistic activity against CD133 protein, which were obtained and designed by means of computer tools, evaluating physicochemical parameters of flexibility, hydrophilicity, hydrophobicity, antigenicity and total charge as described herein, in addition to the modeling of the protein, which allowed selecting 4 regions with the appropriate characteristics. After modeling the selected peptides, CD133 peptide-protein molecular docking was performed, where stable interactions were observed, even showing hydrogen bonds. Finally, the peptides of the invention showed anticancer effects against several cancer cell lines, including cancer cells resistant to conventional treatments such as triple negative breast cancer cells.